Business
TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network
Initial shipment delivered to distributor warehouse supports expansion into B2B pharmacy distribution alongside direct-to-consumer activitiesVancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce its first commercial order in Israel and the successful delivery of an initial...
About this update from Tempramed Technologies Ltd.
[{"type":"text","content":"Initial shipment delivered to distributor warehouse supports expansion into B2B pharmacy distribution alongside direct-to-consumer activities","length":141,"tagName":"p","attribs":{"class":"nfSubHeading"},"className":""},{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - January 6, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) ("TempraMed" or the "Company"), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce its first commercial order in Israel and the successful delivery of an initial shipment to the warehouse of Guri A.A.O. ("Guri"), a leading Israeli medical distribution company.","length":485,"tagName":"p"},{"type":"text","content":"Guri is among the top five distributors in Israel's retail sector and brings more than 50 years of industry leadership. The company exclusively distributes a wide range of internationally recognized brands-including GSK/Haleon oral care products and Cargill's Truvia natural sweeteners-and maintains deep, long-standing relationships with 2,500 of Israel's largest supermarkets, pharmacy chains, HMOs, and independent pharmacies.","length":441,"tagName":"p"},{"type":"text","content":"This milestone marks the commencement of TempraMed's commercial activities within the Israeli retail brick and mortar pharmacy channel, representing a significant expansion of the Company's go-to-market strategy. In addition to its established direct-to-consumer (B2C) activities, the collaboration with Guri adds a dedicated business-to-business (B2B) layer, enabling broader access to TempraMed's temperature-protection solutions through pharmacy networks in Israel.","length":480,"tagName":"p"},{"type":"text","content":"The collaboration in Israel builds on TempraMed's growing portfolio of commercial partnerships across Europe, Asia, and other international markets, reinforcing the Company's global expansion strategy and diversified channel approach.","length":242,"tagName":"p"},{"type":"text","content":"Israel represents a highly advanced healthcare market with strong adoption of injectable therapies, including insulin, GLP-1 receptor agonists, biologics, and emergency medications. As the use of temperature-sensitive medications continues to grow, en...